著者: S E Jones
雑誌名: Cancer. 1973 May;31(5):1092-8. doi: 10.1002/1097-0142(197305)31:5<1092::aid-cncr2820310509>3.0.co;2-b.
Abstract/Text
PMID
4574456 Cancer. 1973 May;31(5):1092-8. doi: 10.1002/1097-0142(1･･･
著者: M H McGinniss, A M Macher, A H Rook, H J Alter
雑誌名: Transfusion. 1986 Sep-Oct;26(5):405-9.
Abstract/Text
Mild-to-profound anemia, thrombocytopenia, and rarely neutropenia have been observed in patients with the acquired immune deficiency syndrome (AIDS). To investigate a possible immune mechanism, blood samples from 28 hospitalized AIDS patients, four asymptomatic homosexual men, four homosexual men with the AIDS-related lymphadenopathy syndrome, 30 hospitalized patients with diseases other than AIDS, and 60 blood donors were tested for the presence of atypical red cell antibodies. Eighteen AIDS patients (64%) had anti-i, nine (32%) had autoanti-U, and 12 (43%) had a positive direct antiglobulin test. One asymptomatic homosexual man and three homosexual men with lymphadenopathy also had anti-i. In contrast, of the 30 patients with diseases other than AIDS and 60 donors, none had anti-U or a positive direct antiglobulin test. One patient with sickle cell disease had anti-i. The mean hemoglobin level of AIDS patients with anti-i or anti-U was significantly lower than the mean hemoglobin level of patients who did not have those antibodies.
PMID
3765030 Transfusion. 1986 Sep-Oct;26(5):405-9.
著者: Fizan Abdullah, Yiyi Zhang, Melissa Camp, Mark I Rossberg, Melinda A Bathurst, Paul M Colombani, James F Casella, Rosemary Nabaweesi, David C Chang
雑誌名: Pediatr Blood Cancer. 2009 Jul;52(7):834-7. doi: 10.1002/pbc.21954.
Abstract/Text
OBJECTIVE: The objective of the present study is to profile the outcome and safety of pediatric patients undergoing splenectomy with hereditary spherocytosis (HS) using a nationwide sample and the Agency for Healthcare Research and Quality (AHRQ) Pediatric Quality Indicators (PDIs).
PATIENTS AND METHODS: A retrospective cross-sectional descriptive analysis of a non-overlapping combination of the National Inpatient Sample (NIS), and Kids' Inpatient Database (KID) databases (1988-2004) were performed. These combined databases contain information from nearly 93 million discharges in the United States. Children with an age at admission of <18 years of age and HS (ICD-9 diagnosis code of 282.0) who underwent total splenectomy (ICD-9 procedure code of 41.5) were identified. Variables of gender, race, co-existing diagnoses, hospital type, and charges adjusted to 2006 dollars, length of stay, inpatient mortality, and complications were collected. PDIs were identified for each patient by linking the data obtained from the NIS and KID databases with the PDIs using the AHRQ Quality Indicators Wizard.
RESULTS: Splenectomy for HS was associated with low morbidity and mortality. Accompanying cholecystectomy and/or appendectomy appeared to be safely performed at the same operation. Of the 13 PDIs identified by AHRQ as potentially avoidable adverse events, none were observed to occur in more than 1% of the patients.
CONCLUSIONS: Based on the results of this study, splenectomy in patients with HS appears safe and to result in a minimal number of potentially preventable complications as identified by the AHRQ PDIs. We have successfully demonstrated use of the indicators to aid in the analysis of a specific surgical procedure within a subset of the pediatric population.
(c) 2009 Wiley-Liss, Inc.
PMID
19214973 Pediatr Blood Cancer. 2009 Jul;52(7):834-7. doi: 10.100･･･
著者: Masaaki Takatoku, Takashi Uchiyama, Shinichiro Okamoto, Yuzuru Kanakura, Kenichi Sawada, Masao Tomonaga, Shinji Nakao, Tatsutoshi Nakahata, Mine Harada, Takashi Murate, Keiya Ozawa, Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
雑誌名: Eur J Haematol. 2007 Jun;78(6):487-94. doi: 10.1111/j.1600-0609.2007.00842.x. Epub 2007 Mar 28.
Abstract/Text
OBJECTIVE: Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are the most common anemias that require transfusion therapy in Japan. This retrospective survey investigated relationships between iron overload, chelation practices, and morbidity/mortality in patients with these diseases.
METHOD: Medical histories of transfusion-dependent patients were assessed at transfusion onset, chelation onset, and study end.
RESULTS: Data were collected from 292 patients with MDS, AA, pure red cell aplasia, myelofibrosis, and other conditions. Patients received a mean of 61.5 red blood cell units during the previous year. Fewer than half (43%) of patients had previously received deferoxamine (DFO) therapy. Only 8.6% received daily/continuous DFO. In all, 75 deaths were reported, with cardiac and liver failure noted in 24.0 and 6.7% of cases. Of these, 97% had ferritin levels >1000 ng/mL. Abnormal cardiac and liver function was observed in 21.9% (14/64) and 84.6% (11/13) of all patients assessed. Effective chelation with DFO resulted in improved serum ferritin, liver enzymes, and fasting blood sugar.
CONCLUSIONS: Mortality is higher in heavily iron-overloaded patients, with liver and cardiac dysfunction being the primary cause. Daily/continuous chelation therapy was effective at reducing iron burden and improving organ function. Chelation therapy should be initiated once serum ferritin levels exceed 1000 ng/mL.
PMID
17391310 Eur J Haematol. 2007 Jun;78(6):487-94. doi: 10.1111/j.1･･･
著者: B C Gilliland
雑誌名: Semin Hematol. 1976 Oct;13(4):267-75.
Abstract/Text
An immune hemolytic anemia occurs in a few patients in whom the concentration of antibody on the red cell is below the level for detection by the usual antiglobulin test. Clinically, these patients are identical to patients with warm type Coombs-positive hemolytic anemia, except for the quantity of antibody on the cell. The course of the hemolytic disease is highly variable. It is postulated that the properties of the antibody in conjunction with the sensitivity of the reticuloendothelial system for antibody-coated cells account for hemolytic anemia occurring with such low concentrations of antibody. The response to steroid therapy and splenectomy, when indicated, is usually favorable.
PMID
1006330 Semin Hematol. 1976 Oct;13(4):267-75.
